IntelliVIX Showcases Advanced AI Monitoring System for Real-Time Safety at CES 2025

IntelliVIX, a leading Vision AI company (Co-CEOs Eunsoo Choi and Jung-hoon Jang), announced on January 9th that it has introduced its next-generation Generative AI Monitoring System, 'Gen AMS,' at CES 2025.

Gen AMS is an innovative solution capable of 24/7 real-time safety monitoring and automated report generation powered by generative AI. It features real-time object detection via CCTV, AI-driven abnormal event alerts, generative AI-based monitoring content analysis and summarization, and multimodal analysis. The system is highly scalable, enabling its application across various fields, including public safety, construction and industrial safety, transportation, and national defense.

Focusing on "preventive safety," Gen AMS leverages generative AI to create monitoring big data, helping to predict and prepare for potential incidents. Additionally, the system is designed to perform reliably even in extreme environments, such as snow, rain, fog, or nighttime, thanks to its advanced AI sensors.

IntelliVIX is showcasing live demonstrations of Gen AMS at its CES booth. Visitors can witness scenarios where the system automatically detects emergencies, summarizes incidents in real time, and generates reports to guide immediate actions.

Eunsoo Choi, CEO of IntelliVIX, stated, "By utilizing generative AI, we are not merely improving monitoring systems but fundamentally transforming the safety paradigm across industries. At IntelliVIX, innovation is not just a goal; it is our responsibility to create a safer world."

In addition, CEO Choi has been appointed as a judge for the CES 2025 Innovation Awards and is participating in selecting this year's winners.

Source:

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.